Abbott Q3 top line up 3%; net income down 157%; non-GAAP EPS up 9%; shares off 1% premarket

|About: Abbott Laboratories (ABT)|By:, SA News Editor

Abbott (NYSE:ABT) Q3 results ($M): Total Revenues: 5,302 (+3.0%); Nutrition: 1,755 (-1.9%); Diagnostics: 1,213 (+4.9%); Est. Pharmaceuticals: 1,012 (+5.3%); Medical Devices: 1,310 (+6.5%).

Net Income: (329) (-156.7%); EPS: (0.22) (-157.9%); Non-GAAP EPS: 0.59 (+9.3%).

Top Performers: Diabetes Care International: 210 (+18.6%); Total Diabetes Care: 306 (+11.3%); Vascular U.S.: 305 (+9.7%); POC International: 24 (+9.1%).

Laggards: Molecular U.S.: 42 (-10.6%); Pediatric Nutrition International: 553 (-9.2%); Total Pediatric Nutrition: 967 (-3.9%).

2016 Guidance: EPS: $0.59 - 0.61 from $1.26 - 1.36; Non-GAAP EPS: $2.19 - 2.21 from $2.14 - 2.24.

Shares are down 1% premarket on light volume.